☆ 4.6 Editorial Material

The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis

NEUROTHERAPEUTICS (2020)

Journal

NEUROTHERAPEUTICS

Volume 17, Issue 3, Pages 968-970

Publisher

SPRINGER

DOI: 10.1007/s13311-020-00907-5

Keywords

Biotin; multiple sclerosis; progressive MS; MS relapse

Categories

Clinical Neurology Neurosciences Pharmacology & Pharmacy

Funding

Sylvia Lawry Physician Fellowship Award from the National Multiple Sclerosis Society [FP-1807-31728]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Clinical Neurology

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis

Sophie Mathais, Xavier Moisset, Bruno Pereira, Frederic Taithe, Jonathan Ciron, Pierre Labauge, Cecile Dulau, David Laplaud, Jerome De Seze, Jean Pelletier, Eric Berger, Christine Lebrun-Frenay, Giovanni Castelnovo, Gilles Edan, Gilles Defer, Patrick Vermersch, Bertrand Bourre, Jean-Philippe Camdessanche, Laurent Magy, Anne-Marie Guennoc, Guillaume Mathey, Thibault Moreau, Olivier Gout, Olivier Heinzlef, Elisabeth Maillart, Sandra Vukusic, Pierre Clavelou

Summary: A French multicenter retrospective study found that high-dose biotin therapy did not significantly increase the risk of clinical relapse in patients with progressive multiple sclerosis compared to a control group. Patients with more relapses before biotin treatment had a higher risk of relapse during treatment.

NEUROTHERAPEUTICS (2021)

Add to Collection

Article Neurosciences

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype

Bruno Brochet, Pierre Clavelou, Gilles Defer, Jerome De Seze, Celine Louapre, Eloi Magnin, Aurelie Ruet, Catherine Thomas-Anterion, Patrick Vermersch

Summary: This literature review focuses on the cognitive deficits observed in secondary progressive multiple sclerosis (SPMS). The findings suggest that cognitive disorders are more frequent and severe in SPMS compared to relapsing-remitting MS (RRMS), and the profile of cognitive impairment differs between these two phenotypes.

BRAIN SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Focal cortical atrophy following transient meningeal enhancement in a progressive multiple sclerosis

Mickael Bonnan, Paul Money, Pauline Desblache, Raluca Marasescu, Lise-Marlene Puvilland, Stephanie Demasles, Camille Dahan, Elsa Krim, Alan Tucholka, Senan Doyle, Bruno Barroso

Summary: Recent studies have found chronic leptomeningeal enhancement in late-acquired FLAIR sequences of secondary progressive multiple sclerosis patients, which may lead to long-term cortical atrophy. A case report of spontaneously remitting meningeal uptake suggests that MRI may overlook the potential burden of previous regressive meningeal lesions.

NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Does health-related quality of life differ between people with relapse onset and progressive onset Multiple Sclerosis?

Hasnat Ahmad, Ingrid van der Mei, Bruce Taylor, Ting Zhao, Qing Xia, Andrew J. Palmer

Summary: The study examined the impact of onset type of multiple sclerosis on overall and disability-severity specific health-related quality of life scores. While PROMS had substantially lower HRQoL than ROMS, there was no difference in mean HRQoL values for each disability level by onset type.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis

Jonathan A. Gernert, Luise Boehm, Michaela Starck, Stefan Buchka, Tania Kuempfel, Ingo Kleiter, Joachim Havla

Summary: Optical coherence tomography (OCT) can be used as a tool for monitoring disease progression in multiple sclerosis (PwMS) patients. A retrospective analysis of OCT data from PwMS and healthy controls (HC) revealed that the relative annual change in the inner retinal layers is associated with worsening ambulation in patients with primary-progressive MS (PPMS).

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Clinical Neurology

How patients with multiple sclerosis acquire disability

Fred D. Lublin, Dieter A. Haering, Habib Ganjgahi, Alex Ocampo, Farhad Hatami, Jelena Cuklina, Piet Aarden, Frank Dahlke, Douglas L. Arnold, Heinz Wiendl, Tanuja Chitnis, Thomas E. Nichols, Bernd C. Kieseier, Robert A. Bermel

Summary: Patients with multiple sclerosis can acquire disability through either relapse-associated worsening or progression independent of relapses. This study found that early progression begins in all phenotypes of the disease, becoming the primary driver of disability accumulation in the progressive phase. Treatments with disease-modifying therapies significantly delay disability accumulation, with the greatest impact seen in patients in the earliest stages of multiple sclerosis.

BRAIN (2022)

Add to Collection

Review Neurosciences

Theiler's virus-induced demyelinating disease as an infectious model of progressive multiple sclerosis

Steven C. Pike, Nora Welsh, Michael Linzey, Francesca Gilli

Summary: This article introduces the etiology of multiple sclerosis (MS) and the importance of verifying viral hypotheses of MS through the TMEV-IDD model. The main mechanisms of CNS autoimmunity, the contribution of different immune cells to TMEV-IDD, and the sexual dimorphism observed in TMEV-IDD and MS are discussed.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2022)

Add to Collection

Article Clinical Neurology

Disability accrual in primary and secondary progressive multiple sclerosis

Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B. Malpas, Ibrahima Diouf, Nahid Moradi, Sifat Sharmin, Guillermo Izquierdo, Sara Eichau, Francesco Patti, Dana Horakova, Eva Kubala Havrdova, Alexandre Prat, Marc Girard, Pierre Duquette, Francois Grand Maison, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Serkan Ozakbas, Maria Pia Amato, Oliver Gerlach, Patrizia Sola, Diana Ferraro, Katherine Buzzard, Olga Skibina, Jeannette Lechner-Scott, Raed Alroughani, Cavit Boz, Vincent Van Pesch, Elisabetta Cartechini, Murat Terzi, Davide Maimone, Cristina Ramo-Tello, Bassem Yamout, Samia Joseph Khoury, Daniele La Spitaleri, Maria Jose Sa, Yolanda Blanco, Franco Granella, Mark Slee, Ernest Butler, Youssef Sidhom, Riadh Gouider, Roberto Bergamaschi, Rana Karabudak, Radek Ampapa, Jose Luis Sanchez-Menoyo, Julie Prevost, Tamara Castillo-Trivino, Pamela A. McCombe, Richard Macdonell, Guy Laureys, Liesbeth Van Hijfte, Jiwon Oh, Ayse Altintas, Koen de Gans, Recai Turkoglu, Anneke van der Walt, Helmut Butzkueven, Steve Vucic, Michael Barnett, Edgardo Cristiano, Suzanne Hodgkinson, Gerardo Iuliano, Ludwig Kappos, Jens Kuhle, Vahid Shaygannejad, Aysun Soysal, Bianca Weinstock-Guttman, Bart Van Wijmeersch, Tomas Kalincik

Summary: This study compared primary and secondary progressive multiple sclerosis (PPMS, SPMS), and found that SPMS has later onset of the progressive phase and slower disability accrual, but higher baseline disability.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Add to Collection

Article Clinical Neurology

Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis

Carmen Alcala Vicente, Laura Lacruz, Francisco Gascon, Sara Carratala, Carlos Quintanilla-Bordas, Maria T. Sanz, Maria Carcelen-Gadea, Javier Mallada, Joan Carreres, Laura Gabaldon Torres, Jose Andres Dominguez, Emmanuel Canizares, Sara Gil-Perotin, Laura Cubas, Raquel Gasque Rubio, Jessica Castillo-Villalba, Francisco Carlos Perez-Miralles, Bonaventura Casanova

Summary: The presence of OCMB and SC-T2 lesions may independently predict the conversion to SPMS.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis

Martina Petruzzo, Antonio Reia, Giorgia T. Maniscalco, Fabrizio Luiso, Roberta Lanzillo, Cinzia Valeria Russo, Antonio Carotenuto, Lia Allegorico, Raffaele Palladino, Vincenzo Brescia Morra, Marcello Moccia

Summary: The study found an association between cardiovascular risk factors and the prognosis of multiple sclerosis (MS). An increase in the Framingham risk score was associated with higher risks of MS relapses, disability, and treatment escalation. Early identification and management of cardiovascular comorbidities should be considered in MS management.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

Neurofilaments in progressive multiple sclerosis: a systematic review

Thomas Williams, Henrik Zetterberg, Jeremy Chataway

Summary: Neurofilament light is consistently associated with current inflammatory activity and future brain atrophy in progressive multiple sclerosis, and is consistently shown to be a marker of treatment response with immunosuppressive disease-modifying therapies. On the other hand, neurofilament heavy evidence is more limited and inconsistent.,UnityEngineNeither neurofilament light nor heavy has shown a consistent treatment response to neuroprotective disease-modifying therapies.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Novel Drugs in a Pipeline for Progressive Multiple Sclerosis

Klaudia Sapko, Anna Jamroz-Wisniewska, Konrad Rejdak

Summary: Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. The pathogenesis of progressive MS (PMS) is complex and causes therapeutic difficulties. The efficacy of currently available anti-inflammatory drugs for PMS is limited in time. In search of innovative solutions, several research studies have evaluated the effectiveness of drugs with neuroprotective or remyelinating effects in PMS. This review discusses the compounds that have entered the clinical assessment phase and explores future prospects for successful PMS treatment.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Risk of secondary progressive multiple sclerosis after early worsening of disability

Winston Dzau, Sifat Sharmin, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Serkan Ozakbas, Oliver Gerlach, Cavit Boz, Pierre Grammond, Murat Terzi, Maria Pia Amato, Daniele La Spitaleri, Cristina Ramo-Tello, Davide Maimone, Elisabetta Cartechini, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, Gerardo Iuliano, Aysun Soysal, Tomas Kalincik

Summary: This study investigated the association between early progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) with the onset and disability accumulation of secondary progressive multiple sclerosis (SPMS). It found that early PIRA and RAW were associated with increased risk of SPMS, but not with the rate of disability progression during SPMS.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Add to Collection

Article Multidisciplinary Sciences

Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis

Ben J. E. Raveney, Wakiro Sato, Daiki Takewaki, Chenyang Zhang, Tomomi Kanazawa, Youwei Lin, Tomoko Okamoto, Manabu Araki, Yukio Kimura, Noriko Sato, Terunori Sano, Yuko Saito, Shinji Oki, Takashi Yamamura

Summary: This study identified a subset of cytotoxic CD4(+) T cells expressing Eomes, known as Eomes(+) Th cells, that are crucially involved in the pathogenesis of secondary progressive MS (SPMS). Eomes levels could act as a biomarker to predict disease worsening in SPMS patients with over 80% accuracy. These findings have significant implications for SPMS biomarkers and potential therapeutic targets.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Clinical Neurology

Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic

Jamie K. Wong, Jerry Lin, Nathan J. Kung, Alexandra L. Tse, Serena J. E. Shimshak, Anna K. Roselle, Francesca M. Cali, Jessie Huang, Joseph M. Beaty, Taylor M. Shue, Saud A. Sadiq

Summary: Multiple sclerosis can present as relapsing-remitting or progressive forms. It is unclear whether these forms represent the same disease or distinct entities with similar pathological features. This study provides evidence that primary progressive multiple sclerosis is characterized by a unique capacity of cerebrospinal fluid (CSF) to induce motor disability and spinal cord pathology, which can be attenuated by removing immunoglobulin G from the CSF. Injection of recombinant antibodies derived from primary progressive multiple sclerosis CSF reproduces the pathology, suggesting an antibody-mediated and distinct pathogenic mechanism for this form of the disease. These findings have important implications for developing targeted therapies for primary progressive multiple sclerosis patients.

BRAIN (2023)

Add to Collection

Article Clinical Neurology

Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder

Gabrielle Macaron, Jean Khoury, James Bena, Meagan Seay, Robert A. Bermel, Jeffrey A. Cohen, Mary R. Rensel

Summary: This study found that early onset age is closely associated with the occurrence of SRVL in NMOSD patients, with those younger than 21 years old more likely to develop SRVL. For these patients, high-efficacy therapies should be considered for first-line treatment.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Advances in the Treatment of Multiple Sclerosis

Carolyn Goldschmidt, Marisa P. McGinley

NEUROLOGIC CLINICS (2021)

Add to Collection

Editorial Material Clinical Neurology

MRI findings in blinded trials should be available to treating physicians - No

Sarah B. Simmons, Jeffrey A. Cohen

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment

Jeffrey A. Cohen, Michelle H. Cameron, Myla D. Goldman, Andrew D. Goodman, Aaron E. Miller, Anne Rollins, Lily Llorens, Rajiv Patni, Robert Elfont, Reed Johnson

Summary: The study demonstrates that 274mg ADS-5102 is more effective in improving walking speed compared to placebo, meeting its primary endpoint. While there was a dose response for some secondary measures and adverse events, it was not significant.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Jeffrey A. Cohen, Robert A. Bermel, Cynthia Grossman, Carrie M. Hersh, Megan Hyland, Ellen M. Mowry, Robert Naismith, Maria L. Naylor, Jacqueline Nicholas, Rajani Rajbhandar, Carol M. Singh, Mar Tintore, Ana Zabalza, Tjalf Ziemssen, James R. Williams, Xavier Montalban

Summary: For patients with multiple sclerosis using anti-CD20 therapies and S1PRMs, their IgG response to the SARS-CoV-2 vaccine is reduced, while other treatment methods can preserve IgG response.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

Jutta Gaertner, Stephen L. Hauser, Amit Bar-Or, Xavier Montalban, Jeffrey A. Cohen, Anne H. Cross, Kumaran Deiva, Habib Ganjgahi, Dieter A. Haering, Bingbing Li, Ratnakar Pingili, Krishnan Ramanathan, Wendy Su, Roman Willi, Bernd Kieseier, Ludwig Kappos

Summary: The study showed that ofatumumab is more effective and safer than teriflunomide in recently diagnosed, treatment-naive patients with relapsing multiple sclerosis. Compared with teriflunomide, ofatumumab significantly reduced the annualized relapse rate, delayed confirmed disability worsening, and delayed progression independent of relapse activity.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study

Corey C. Ford, Jeffrey A. Cohen, Andrew D. Goodman, John W. Lindsey, Robert P. Lisak, Christopher Luzzio, Amy Pruitt, John Rose, Horea Rus, Jerry S. Wolinsky, Shaul E. Kadosh, Emily Bernstein-Hanlon, Yafit Stark, Jessica K. Alexander

Summary: The study found that early initiation of GA was more effective in maintaining clinical benefits and delaying disease progression compared to delayed treatment. Additionally, it showed no new safety concerns with GA long-term treatment.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis

Jeffrey A. Cohen, Fred D. Lublin, Christoper Lock, Daniel Pelletier, Tanuja Chitnis, Munish Mehra, Yael Gothelf, Revital Aricha, Stacy Lindborg, Chaim Lebovits, Yossef Levy, Afsaneh Motamed Khorasani, Ralph Kern

Summary: This open-label phase II study evaluated the safety and efficacy of autologous mesenchymal stem cell neurotrophic factor-secreting cells in progressive multiple sclerosis. Preliminary findings suggest that this treatment may have the potential to improve symptoms and reduce inflammation, but further randomized studies are needed for confirmation.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis

Ebtesam Alshehri, Jeffrey A. Cohen, Daniel Ontaneda, Kunio Nakamura, Scott Husak, Thomas E. Love, Robert J. Fox, Farren B. S. Briggs, Devon S. Conway

Summary: Smoking is associated with an increased risk of multiple sclerosis (MS) and disability worsening. This study quantified the impact of smoking on processing speed and brain volume in MS patients and explored the longitudinal relationship between smoking and changes in processing speed. The results showed that smoking was associated with lower processing speed and reduced gray matter fraction. These observations support the importance of smoking cessation counseling in MS management.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis

Kunio Nakamura, Yufan Zheng, Kedar R. Mahajan, Jeffrey A. Cohen, Robert J. Fox, Daniel Ontaneda

Summary: This study aimed to evaluate the effect of ibudilast on thalamic tissue integrity and volume in patients with multiple sclerosis. The results showed that ibudilast had a treatment effect on thalamic magnetization transfer ratio (MTR) but not on thalamic volume. Thalamic volume was associated with lesion volume, while thalamic MTR was associated with disability progression.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension

Stephen L. Hauser, Ronald Zielman, Ayan Das Gupta, Jing Xi, Dee Stoneman, Goeril Karlsson, Derrick Robertson, Jeffrey A. Cohen, Ludwig Kappos

Summary: Ofatumumab demonstrates superior efficacy and favorable safety in the treatment of relapsing multiple sclerosis. In the long term, it has a favorable benefit-risk profile for patients with this condition.

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Editorial Material Clinical Neurology

Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol (in press)

Jeffrey A. Cohen

MULTIPLE SCLEROSIS JOURNAL (2023)

Add to Collection

Article Clinical Neurology

Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study

Yang Mao-Draayer, Jeffrey A. Cohen, Amit Bar-Or, May H. Han, Barry Singer, Ian M. Williams, Xiangyi Meng, Chelsea Elam, Jamie L. Weiss, Gina Mavrikis Cox, Marina Ziehn, Bruce A. C. Cree

Summary: This study investigated the temporal effects and safety outcomes of fingolimod on immune cell subsets. The results showed reductions in all monitored peripheral lymphocyte subsets in fingolimod-naive participants, while levels remained stable in those continuously treated with fingolimod. No safety concerns were observed.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)

Add to Collection

Article Clinical Neurology

Perspectives and experiences with COVID-19 vaccines in people with MS

John R. Ciotti, Dana C. Perantie, Brandon P. Moss, Kathryn C. Fitzgerald, Jeffrey A. Cohen, Ellen M. Mowry, Robert T. Naismith, Salim Chahin

Summary: Most individuals with MS surveyed plan to receive the COVID-19 vaccine. People with MS experience similar side effects to the general population, and few experience transient MS symptom worsening. Variables impacting vaccine willingness include medical comorbidities and following infection prevention precautions.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2022)

Add to Collection

Article Clinical Neurology

Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis

Deja R. Rose, Khmad Z. Mahadeen, Alise K. Carlson, Sarah M. Planchon, Jennifer Sedlak, Scott Husak, Robert A. Bermel, Jeffrey A. Cohen, Brandon P. Moss

Summary: Studies have shown reduced serological response to vaccines in patients on anti-CD20 agents, but limited data exist on vaccine efficacy in patients on disease modifying therapy (DMT). This study aimed to investigate breakthrough COVID-19 cases in vaccinated people with multiple sclerosis on DMT. Results showed that a small percentage of fully vaccinated patients on DMT were diagnosed with COVID-19, with most cases on anti-CD20 therapy and only a few requiring hospitalization. Further research is needed to analyze the risk of COVID-19 in patients on different therapies, especially in the context of emerging variants.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.